COMPOSITION FOR PROMOTING GOBLET CELL PROLIFERATION OR MUCIN SECRETION COMPRISING THYMOSIN BETA 4 OR DERIVATIVE THEREOF AS ACTIVE INGREDIENT
A composition containing thymosin beta-4, an isoform of thymosin beta-4, an analogue thereof, or a derivative of thymosin beta-4 as an active ingredient and its use in promoting goblet cell proliferation and/or increasing mucin secretion are disclosed. The composition increases the expression of Muc5AC, Muc1, Muc4, and Muc16 and, thus, is considered to have an excellent effect on goblet cell or mucin-related diseases.
1 - 19 . (canceled)
20 . A method for promoting goblet cell proliferation or mucin secretion in epithelial tissue of a subject in need thereof, comprising administering an effective amount of a composition comprising thymosin beta 4, a thymosin beta 4 isoform, or an analog or a derivative thereof to the subject as an active ingredient.
21 . The method of claim 20 , wherein the thymosin beta 4 has the amino acid sequence represented by SEQ ID NO: 1.
22 . The method of claim 20 , wherein the derivative of thymosin beta 4 has a mutated N-terminus or C-terminus of thymosin beta 4.
23 . The method of claim 20 , wherein a concentration of the thymosin beta 4, isoform or a derivative thereof in the composition is 0.02% (w/v) to 0.5% (w/v).
24 . The method of claim 20 , wherein the composition further comprises acetic acid, citric acid, a salt thereof, or a hydrate of the salts.
25 . The method of claim 20 , wherein the composition further comprises sodium chloride, potassium chloride, calcium chloride dihydrate, and magnesium chloride hexahydrate.
26 . A method of preventing or treating goblet cell-related or mucin-related disease in a subject in need thereof, comprising administering an effective amount of a composition comprising thymosin beta 4, a thymosin beta 4 isoform, or an analog or a derivative thereof to the subject as an active ingredient.
27 . The method of claim 26 , wherein the thymosin beta 4 has the amino acid sequence represented by SEQ ID NO: 1.
28 . The method of claim 26 , wherein the derivative of thymosin beta 4 has a mutated N-terminus or C-terminus of thymosin beta 4.
29 . The method of claim 26 , wherein a concentration of the thymosin beta 4, isoform, or a derivative thereof in the composition is 0.02% (w/v) to 0.5% (w/v).
30 . The method of claim 26 , wherein the composition further comprises acetic acid, citric acid, a salt thereof, or a hydrate of the salt.
31 . The method of claim 26 , wherein the composition further comprises sodium chloride, potassium chloride, calcium chloride dihydrate, and magnesium chloride hexahydrate.
32 . The method of claim 26 , wherein the mucin-related disease is gastritis, gastric ulcer, enteritis, ulcerative colitis, or dry eye.